Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study

被引：7
|
作者：
Gannan, Emma [1 ,2 ,3 ]
Khoo, Jeremy [4 ]
Nightingale, Sophie [5 ]
Suhardja, Thomas Surya [6 ]
Lippey, Jocelyn [7 ]
Keane, Holly [8 ]
Tan, Kian Jin [9 ]
Clouston, David [4 ]
Gorelik, Alexandra [10 ]
Mann, Gregory Bruce [1 ,2 ,11 ]
机构：
[1] Royal Melbourne Hosp, Breast Serv, Parkville, Vic, Australia
[2] Royal Womens Hosp, Parkville, Vic, Australia
[3] Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia
[4] Focus Pathol, East Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Dept Surg, East Melbourne, Vic, Australia
[6] Monash Med Ctr, Dept Surg, Clayton, Vic, Australia
[7] Austin Hosp, Dept Surg, Heidelberg, Vic, Australia
[8] Alfred Hosp, Dept Surg, Melbourne, Vic, Australia
[9] St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic, Australia
[10] Univ Melbourne, Royal Melbourne Hosp, Melbourne EpiCtr, Parkville, Vic, Australia
[11] Univ Melbourne, Dept Surg, Parkville, Vic, Australia
来源：
BREAST JOURNAL | 2016年 / 22卷 / 04期
关键词：
ACOSOG Z0011 trial; axillary lymph node dissection; breast cancer; sentinel lymph node biopsy; SENTINEL-NODE; AXILLARY DISSECTION; AMERICAN-COLLEGE; CLINICAL-PRACTICE; Z0011; TRIAL; BIOPSY; RECURRENCE; SURGEONS; IMPACT; MICROMETASTASES;
D O I：
10.1111/tbj.12595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009-2010 to 2011-2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009-2010 and 22.2% in 2011-2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.
引用
收藏
页码：413 / 419
页数：7
相关论文
共 50 条
  • [41] Altered sirtuin expression is associated with node-positive breast cancer
    N Ashraf
    S Zino
    A MacIntyre
    D Kingsmore
    A P Payne
    W D George
    P G Shiels
    British Journal of Cancer, 2006, 95 : 1056 - 1061
  • [42] Targeting and limiting surgery for patients with node-positive breast cancer
    Abigail S. Caudle
    Henry M. Kuerer
    BMC Medicine, 13
  • [43] Dose-dense chemotherapy for node-positive breast cancer
    Citron, ML
    ANNALS OF INTERNAL MEDICINE, 2005, 142 (03) : 227 - 227
  • [44] Altered sirtuin expression is associated with node-positive breast cancer
    Ashraf, N.
    Zino, S.
    MacIntyre, A.
    Kingsmore, D.
    Payne, A. P.
    George, W. D.
    Shiels, P. G.
    BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 1056 - 1061
  • [45] Concomitant adjuvant chemoradiotherapy effective in node-positive breast cancer
    Pippa Murdie
    Nature Clinical Practice Oncology, 2006, 3 (6): : 289 - 290
  • [46] Microsatellite instability is correlated with lymph node-positive breast cancer
    DeMarchis, L
    Contegiacomo, A
    DAmico, C
    Palmirotta, R
    Pizzi, C
    Ottini, L
    Mastranzo, P
    Figliolini, M
    Petrella, G
    Amanti, C
    Battista, P
    Bianco, AR
    Frati, L
    Cama, A
    MarianiCostantini, R
    CLINICAL CANCER RESEARCH, 1997, 3 (02) : 241 - 248
  • [47] Axillary Lymphadenectomy in Sentinel Lymph Node-Positive Breast Cancer
    Zhu, Liling
    Chen, Kai
    Jacobs, Lisa K.
    Aft, Rebecca
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (01) : 28 - 31
  • [48] Targeting and limiting surgery for patients with node-positive breast cancer
    Caudle, Abigail S.
    Kuerer, Henry M.
    BMC MEDICINE, 2015, 13
  • [49] Prognostic variables in node-negative and node-positive breast cancer - editorial
    Giampietro Gasparini
    Breast Cancer Research and Treatment, 1998, 52 : 321 - 331
  • [50] Node-positive breast cancer: Which are the best chemotherapy regimens?
    Janni, Wolfgang
    Rack, Brigitte
    Harbeck, Nadja
    Bauerfeind, Ingo
    Sommer, Harald
    Friese, Klaus
    BREAST CARE, 2008, 3 (04) : 244 - 250
12345